कृपया अन्य खोज का प्रयास करें
Aelis Farma SA, a clinical-stage biotechnology company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders. It is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; and AEF0217, a drug candidate, which is in phase I/II clinical trials to treat cognitive deficits observed in Down syndrome, as well as other cognitive impairments. The company was incorporated in 2013 and is headquartered in Bordeaux, France.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Francois Thomas | 67 | 2022 | Censor |
Karen Linehan | 65 | 2022 | Independent Director |
Pier Vincenzo Piazza | 63 | 2017 | CEO & Director |
Irina Staatz-Granzer | 64 | 2022 | Independent Director |
Brahim Guetarni | 53 | 2021 | Director |
Keith Humphreys | - | - | Member of Scientific Advisory Board |
Robert C. Malenka | - | - | Chairman of the Scientific Advisory Board |
Karina Hansen | 51 | 2022 | Independent Director |
Daniele Piomelli | - | - | Member of Scientific Advisory Board |
Markus Heilig | - | - | Member of Scientific Advisory Board |
Anders Gersel Pedersen | 73 | 2020 | Independent Chairman of the Board |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है